High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Rescue for Pediatric Brain Tumor Patients: A Single Institution Experience from UCLA

Table 3

HDCT-AHSCR and outcome.

Patient number	Age at first AHSCR (years)	Status at AHSCR	HDCT prior to AHSCR	Number of AHSCR	Recurrence after transplant	Outcome	Latest Lansky/Karnovsky performance scores
1	15.2	PR	^¶CP, TT, VP	1	No	Deceased	—
2	16.4	CR	̂‌VP, TT	1	No	Alive	100
3	1.6	CR	^¶CP, TT, VP	1	No	Alive	90
4	17.8	PR	̂‌VP, TT	1	No	Alive	90
5	3.2	PR	*CP, TT	3	Yes	Alive	90 (Prior to recurrence)
6	5.9	CR	^¶CP, TT, VP	1	No	Alive	90
7	1.2	CR	^¶CP, TT, VP	1	No	Alive	90
8	2.8	SD	*CP, TT	3	Yes	Alive	90
9	20.0	SD	^¶CP, TT, VP	1	Yes	Deceased	—
10	4.9	CR	CDDP,VCR,CPM	4	No	Alive	100
11	2.3	CR	^¶CP, TT, VP	1	No	Alive	90
12	2.5	CR	*CP, TT	3	No	Alive	100
13	15.3	SD	CPM, Melphalan	1	Yes	Deceased	—
14	0.7	SD	*CP, TT	3	Yes	Deceased	—
15	2.7	PR	*CP, TT	3	Yes	Deceased	—
16	2.4	CR	*CP, TT	3	No	Alive	100
17	2.5	CR	*CP, TT	3	No	Alive	100
18	2.0	CR	*CP, TT	3	No	Alive	90

PR: Partial remission, CR: Complete remission, SD: Stable disease. ^¶CP, TT, VP: Carboplatin (500 mg/m²/dose or 16.7 mg/kg/dose for <3 y/o) on days −8, −7, and−6; Thiotepa (300 mg/m²/dose or 10 mg/kg/dose for < 3 y/o) and Etoposide (250 mg/m²/dose or 8.3 mg/kg/dose for <3 y/o) on days −5, −4, and−3, *CP, TT: Carboplatin 17 mg/kg/dose, and Thiotepa 10 mg/kg/dose, given IV over 2 hours once daily for 2 days on days −3 and −2, ̂‌VP, TT: Thiotepa 300 mg/m2/dose and Etopposide 500 mg/m2/dose once daily on days −5, −4, and −3, CDDP: Cisplatin, CPM: Cyclophosphamide, and VCR: Vincristine.